MLTX — MoonLake Immunotherapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Matterport, Grove Collaborative, Toast
MoonLake's skin disease lead drug offers better safety than rivals- Jefferies
Brief: Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of Nanobody® Sonelokimab In Patients With Active Psoriatic Arthritis
Brief: Merck Healthcare Reports 8.3% Passive Stake In Moonlake Immunotherapeutics
Brief: MoonLake Immunotherapeutics Signs Development And Manufacturing Agreement With Vetter Pharma International GmbH
Cowen starts coverage on MoonLake with 'outperform'
Brief: Moonlake Immunotherapeutics Starts Phase 2 Trial Of NanobodySonelokimab In Patients With Moderate-To-Severe Hidradenitis Suppurativa
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:31 PM
Brief: Moonlake Immunotherapeutics AG And Helix Acquisition Corp. Announce Business Combination Agreement
NASDAQ RESUMED AT 07:30 AM
NASDAQ TRADE HALT HALT NEWS DISSEMINATION AT 07:00 AM
Brief: Helix Acquisition Corp - On April 27, Jay Scollins Notified Co Of His Decision To Resign From His Position As CFO, Effective April 30
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:02 AM